CDH13

Aliases
  • CDH13
  • H-cadherin
  • H-cadherin (heart)
  • P105
  • T-cad
  • T-cadherin
  • cadherin 13
  • heart-cadherin
  • truncated-cadherin
Description
CDH13 is a member of the cadherin superfamily. The encoded protein is a calcium dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a transmembrane region but, unlike the typical cadherin superfamily member, lacks the highly conserved cytoplasmic region. This particular cadherin is a putative mediator of cell-cell interaction in the heart and may act as a negative regulator of neural cell growth. The gene locus is hypermethylated or deleted in breast, ovarian and lung cancers.
Attributes
QA State
Accepted
Type
Genomic
HGNC Name
CDH13
Certifications
  • None
QA State for Esophagus
Accepted
Organ-Specific Notes

Esophageal adenocarcinoma risk in Barrett's esophagus is increased 30- to 125- fold versus the general population. Among all Barrett's esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.

Performance Comment

Levels of CDH13 hypermethylation have been shown to discriminate esophageal adenocarcinoma from esophageal squamous cell carcinoma and normal esophagus. CDH13 is also being investigated as a biomarker for progression from Barrett's esophagus to esophageal adenocarcinoma. Studies are ongoing.

Supporting Study Data
Barretts Esophagus Methylation Profiles
Study phase on the esophagus: 3

We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with BE, we will perform a multi-center study of FISH and hypermethylation markers as possible prognostic factors in BE. The centers will select from their cohorts who have progressed to HGD or to adenocarcinoma of the esophagus ("progressors"), and who also donated samples prior to the development of cancer, when their histology was felt to be benign. These subjects will be compared to individuals who have been under endoscopic surveillance, but who have not progressed to HGD or EAC ("non-progressors"). Using this approach, we hope to identify promising markers for risk stratification in BE. We expect to be able to make successful application for a prospective study of markers identified in this case-control study.

View Protocol
Decision rule: PMID:18729198
Barretts Esophagus Methylation Profiles
Study phase on the esophagus: 3

We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with BE, we will perform a multi-center study of FISH and hypermethylation markers as possible prognostic factors in BE. The centers will select from their cohorts who have progressed to HGD or to adenocarcinoma of the esophagus ("progressors"), and who also donated samples prior to the development of cancer, when their histology was felt to be benign. These subjects will be compared to individuals who have been under endoscopic surveillance, but who have not progressed to HGD or EAC ("non-progressors"). Using this approach, we hope to identify promising markers for risk stratification in BE. We expect to be able to make successful application for a prospective study of markers identified in this case-control study.

View Protocol
Decision rule: PMID:18729198
Esophagus-Specific Protocols
  • No organ-level protocols specified for esophagus.
Esophagus-Specific Publications
  • No organ-level publications were listed for esophagus.
Esophagus-Specific Resources
  • No organ-level resources were given for esophagus.
Certifications
  • None
QA State for Lung
Under Review

 Non-Public Biomarker

Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.